Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol.
Janine StutterheimInge M van der SluisPaola de LorenzoJulia AltenPhilip AncliffeAndishe AttarbaschiBenoit BrethonAndrea BiondiMyriam CampbellGiovanni CazzanigaGabriele EscherichAlina FersterRishi Sury KotechaBirgitte LausenChi-Kong LiLuca Lo NigroFranco LocatelliRolf MarschalekClaus MeyerMartin SchrappeJan StaryAjay VoraJan ZunaVincent H J van der VeldenTomasz SzczepanskiMaria Grazia ValsecchiRob PietersPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
This study provides support for the idea that induction therapy selects patients for subsequent therapy; infants with high EOI MRD may benefit from AML-like consolidation (DFS 45.9% v 23.2%), whereas patients with low EOI MRD may benefit from ALL-like consolidation (DFS 78.2% v 45.0%). Patients with positive EOC MRD had dismal outcomes. These findings will be used for treatment interventions in the next Interfant protocol.
Keyphrases
- acute lymphoblastic leukemia
- end stage renal disease
- newly diagnosed
- randomized controlled trial
- ejection fraction
- chronic kidney disease
- allogeneic hematopoietic stem cell transplantation
- acute myeloid leukemia
- peritoneal dialysis
- physical activity
- type diabetes
- metabolic syndrome
- patient reported outcomes
- replacement therapy
- bone marrow
- real time pcr
- quantum dots
- smoking cessation